New combo therapy shows promise for Hard-to-Treat vulvar cancer
NCT ID NCT04430699
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining standard chemotherapy (cisplatin) and radiation with an immunotherapy drug (pembrolizumab) can shrink or control advanced vulvar cancer that cannot be removed by surgery. The trial includes 24 adults with unresectable, recurrent, or metastatic vulvar squamous cell carcinoma. The goal is to improve response rates and delay cancer recurrence.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VULVAR CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- New imaging tool could help surgeons detect hidden cancer cells during surgery
- New drug combo targets HPV-Driven cancers in phase II trial
- Two-Drug combo aims to shrink vulvar tumors before surgery
- New study aims to uncover why some women have worse sexual side effects from radiation
- Question list may empower gynecologic cancer patients in clinic